ABSTRACT
Objectives: CD43 can be useful in routine flow cytometry. We conducted a systematic review aiming to describe when CD43 is used by flow cytometry in malignant hematology and to determine its value in these settings.
Methods: Systematic review of MEDLINE (search ‘CD43’ AND ‘flow cytometry,’ starting in 2010).
Results: Twenty-one of 103 entries retrieved were included in this systematic review. CD43 is used in three settings: 1) in the classification of mature B cell lymphoproliferative disorders, 2) as part of a strategy to quantify residual disease in chronic lymphocytic leukemia (CLL) and 3) to help classify CD10-positive B cell populations. In this section, the published data is summarized, the clinical usefulness in each of these settings is evaluated and illustrative cases are shown.
Conclusion: CD43 has a growing role in the diagnosis and management of B cell malignancies; it has become essential for the classification of B cell lymphoproliferative disorders and may be of help in the differential diagnosis of CD10-positive lymphomas by FC. It is also required for optimal quantification of CLL residual disease, which will soon be used to guide therapeutic decisions.
Article highlights
This is a systematic review of the use of CD43 by flow cytometry in malignant hematology
Of 103 retrieved MEDLINE entries, 21 were included, based on pre-defined criteria, corresponding to 3 roles
We find a growing and important role for CD43 in the classification of B cell lymphoproliferative disorders
We find a well-established and essential role for CD43 in the quantification of CLL residual disease
We find an unconfirmed, potentially minor role for CD43 in the classification of nodal CD10-positive B cell lymphomas
Author contributions
M Sorigue conceived and wrote the manuscript.
Acknowledgments
The author thanks the CERCA Programme/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support
Declaration of interest
M Sorigue receives travel expenses and honoraria from Beckman Coulter. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Supplementary material
Supplemental data for this article can be accessed here.